-
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes
Review
(3983) Views (1198) Full article downloads
Author: Jonathan K Reynolds
Published Date July 2009
Volume 2009:2 Pages 127 - 134
DOI: http://dx.doi.org/10.2147/DMSO.S4637
Jonathan K Reynolds
Washington State University, College of Pharmacy, Pullman, WA, USA
Abstract: JanumetTM, a fixed dose combination of sitagliptin/metformin HCL manufactured by Merck Pharmaceuticals, has received US Food and Drug Administration approval for treatment of patients with type 2 diabetes, that are inadequately controlled, either by sitagliptin or metformin alone or together in free-dose combination form. Sitagliptin, an inhibitor of the enzyme DDP-4, assists patients with type 2 diabetes mellitus to achieve glycemic control. It has been shown to be safe and effective at 100 mg daily doses. The effect of giving sitagliptin in combination with metformin is thought to have a complimentary and possibly additive effect on glycemic control.
Keywords: sitagliptin, metformin, fixed-dose combination, dipeptidyl peptidase-4 inhibitor, DPP-4 inhibitor
- Testimonials
"You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio
- Alogliptin: a new addition to the class of DPP-4 inhibitors
- Self-monitoring of blood glucose in noninsulin-treated type 2 diabetes: an overview
- The economic impact of obesity in the United States
- Adipose inflammation: cause or consequence of obesity-related insulin resistance
